1. Canada Stocks

  2. •

    Financial Services

  3. •

    Financial - Conglomerates
Pharmacorp Rx Inc.

Pharmacorp Rx Inc.

PCRX.V
Pharmacorp Rx Inc.CA flagToronto Stock Exchange Ventures
0.42
CAD
+0.03
- -
82.38MMarket Cap
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
0.07
0.17
0.18
Basic EPS, GAAP
- -
-0.02
-0.01
-0.01
-0.01
-0.01
Free Cash Flow per Basic Share
- -
- -
-0.01
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
0.02
0.07
0.06
0.26
0.3
0.3
Tangible Book Value per Share
0.02
0.07
0.06
0.12
0.12
0.13
Basic Weighted Avg Shares
- -
33
40
82
125
155
Sales/Revenue/Turnover
- -
- -
- -
6
21
27
Operating Margin (%)
- -
- -
- -
-27.41
-5.92
-4.77
Depreciation Expense
- -
- -
- -
- -
1
1
Net Income, GAAP
- -
-1
- -
-1
-1
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-18.14
-6.81
-4.16
Working Capital
1
3
2
13
24
25
LT Debt
- -
- -
- -
1
4
4
Total Equity
1
3
2
31
52
53
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-28.02
-18.85
-6.44
-3.46
-2.75

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1
1
1
LT Borrowings
3
3
3
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
174
174
174
Market Capitalization
79
76
87

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
30
28
29
Cash, Cash Equivalents & STI
26
23
24
Accounts Receivable, Net
1
1
1
Inventories
3
3
3
Total Current Liabilities
6
3
4
Payables & Accruals
5
2
3
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
71.01%
Free Cash Flow
- -
- -
-245.02%
Net Income, GAAP
- -
- -
35.31%
Sales/Revenue/Turnover
- -
- -
260.57%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
1
4
6
2025
4
4
5
8
21
2026
7
8
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
-0.01
-0.01
- -
-0.01
2025
- -
- -
- -
- -
-0.01
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Grady Brown
Full Time Employees
5
Sector
Financial Services
Industry
Financial - Conglomerates
Address
303 Wellman Lane Saskatoon SK Canada S7T 0J1
IPO Date
Sep 29, 2022
Website
pharmacorprx.ca
Similar Companies
Calisa Acquisition Corp (ALIS)
Dr. Phone Fix Canada Corporation (DPF.V)
Miluna Acquisition Corp Warrant (MMTXW)
The MEDIA GLOBO Corporation (MGLO)
Imagi International Holdings Limited (0585.HK)
Kingdom Holding Company (4280.SR)
Business
PharmaCorp Rx Inc. operates as a Canadian pharmacy acquisition, ownership and services platform that acquires, integrates and operates community pharmacies, principally under the PharmaChoice Canada banner. The Company provides prescription dispensing and related pharmacy services; prescription-file and patient-record transfers; pharmacist consultations; medication compounding; over-the-counter medicines; health, wellness and personal-care products; convenience and front-of-store retail merchandise; lifestyle programs; and operational, strategic and capital support to pharmacist equity partners and pharmacy owners pursuing succession or business-sale transactions. PharmaCorp targets independent and bannered community pharmacies and supports continuity of care, local pharmacist ownership and transition planning for retiring owners. The Company operates pharmacies across Canada, including Eastern Canada, Ontario and Western Canada, and rebrands eligible independent locations under the PharmaChoice Canada platform pursuant to its strategic alliance with PharmaChoice Canada. Incorporated in 2021, PharmaCorp Rx Inc. is headquartered in Saskatoon, Saskatchewan, Canada. In 2026, the Company accelerated its national consolidation strategy by completing acquisitions of eight PharmaChoice Canada-bannered pharmacies in Eastern Canada, an Ontario pharmacy and a Western Canadian pharmacy, increasing its operating network to 16 PharmaChoice Canada-bannered locations; it also completed prescription-file acquisitions intended to consolidate patient volume into existing pharmacies. In July 2026, PharmaCorp completed a C$11.5 million bought-deal public offering to fund future acquisitions and working-capital needs. In August 2026, the Company entered into definitive agreements to acquire an additional PharmaChoice Canada-bannered pharmacy in Western Canada and the prescription files, patient records and related data of an I.D.A.-bannered pharmacy, while continuing to evaluate further pharmacy acquisition opportunities across Canada.